15 January, 2021

Against Vaccine Nationalism

Ensuring ­access to the Covid vaccine is a challenge as it is needed everywhere at the same time.

Against Vaccine Nationalism

The good news is that there are currently more than 200 candidate vaccines in development. With 10 in the last stage of efficacy testing, we should begin to find out which ones will be safe and effective in the next few months. This is important as historically not all vaccine candidates, even those that make it to clinical trials, have successfully made it to licensure. Therefore, it is critical to have a portfolio of vaccines of different types under development. It is also why, together with our partners—the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO—Gavi is ­co-leading COVAX, which will act as a platform to support the development, manufacturing, procurement and delivery of as wide a range of COVID-19 vaccine candidates as possible.

To increase our chances of success, COVAX has created the world’s largest and most diverse portfolio of these vaccines, with nine candidate vaccines already in development, a further nine under evaluation, and options to include other vaccines. This would help us reach our target of procuring...



To read this piece, and more such stories in India's most exciting and exacting magazine, plus get access to our 25-year archives goldmine, please subscribe.

Latest Magazine

January 25, 2021

other articles from the issue

articles from the previous issue

Other magazine section